Breaking News Instant updates and real-time market news.

XLU

Utilities SPDR

, UNG

United States Natural Gas Fund

09:40
06/19/17
06/19
09:40
06/19/17
09:40

Unusually active option classes on open June 19th

Unusual total active option classes on open include: Utilities Sector SPDR (XLU), UNG (UNG), Costco (COST), Consumer Staples Sector SPDR (XLP), Whole Foods (WFM), AK Steel (AKS), iShares Silver Trust (SLV), Valeant (VRX), US Steel (X), and Rite Aid (RAD).

XLU

Utilities SPDR

UNG

United States Natural Gas Fund

COST

Costco

$167.11

-12.95 (-7.19%)

XLP

Consumer Staples Sector SPDR

WFM

Bought by AMZN

$42.68

9.62 (29.10%)

AKS

AK Steel

SLV

iShares Silver Trust

VRX

Valeant

X

U.S. Steel

RAD

Rite Aid

  • 19

    Jun

  • 25

    Jul

  • 23

    Aug

  • 24

    Aug

XLU Utilities SPDR

UNG United States Natural Gas Fund

COST Costco
$167.11

-12.95 (-7.19%)

06/19/17
RBCM
06/19/17
NO CHANGE
RBCM
Wal-Mart, Costco could be hurt by Whole Foods deal, says RBC Capital
RBC Capital analyst Scot Ciccarelli warns that Wal-Mart (WMT) and Costco (COST) could be hurt by the Whole Foods deal. The analyst says that "combining Whole Foods' high-end reputation with a logistics juggernaut like Amazon is clearly a danger" to Costco and Walmart. He thinks that Whole Foods could extend the hours in which it allows customers to buy products online and pick them up in stores, and he thinks that food delivery could become much more popular in the wake of the deal. He notes that Wal-Mart has spent a great deal of time and money on "improving its fresh and omni-channel offerings." The analyst says that Costco will be more protected due to what he sees as its "differentiated retail experience."
06/16/17
06/16/17
DOWNGRADE

Neutral
Costco downgraded to Neutral from Conviction Buy at Goldman Sachs
As previously reported, Goldman downgraded Costco (COST) to Neutral from Conviction Buy and lowered its price target to $176 from $197. Analyst Matthew Fassler believes Costco's valuation will be capped due to Amazon's (AMZN) ongoing moves into consumables, online investments by Wal-Mart (WMT) and fading fundamental catalysts. He believes Amazon will offer superior pricing and delivery competency versus incumbents but does not anticipate meaningful erosion in warehouse business trends any time soon.
06/19/17
COWN
06/19/17
NO CHANGE
Target $1125
COWN
Outperform
Amazon Prime the long-term driver of retail business, says Cowen
Cowen analyst John Blackledge said Amazon's (AMZN) Prime service is the long-term driver of its retail business and as they continuously improve their value proposition, it will drive higher Prime subscriptions and further market share gains. Those gains may have a negative impact on Costco (COST) and Sam's Club (WMT) as the warehouse clubs have seen opposite trends as Prime has increased subscriptions, added Blackledge, who reiterated his Outperform rating and $1,125 price target on Amazon.com shares.
06/19/17
DBAB
06/19/17
DOWNGRADE
Target $172
DBAB
Hold
Costco downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Paul Trussell downgraded Costco (COST) to Hold and lowered his price target for the shares to $172 from $187. Positive pipeline catalysts have played out while competition is intensifying with Amazon.com (AMZN) and Wal-Mart (WMT) accelerating in-store and online efforts, Trussell tells investors in a research note titled "Past Its Prime? Downgrade to Hold." He believes Amazon's acquisition of Whole Foods (WFM) is a "game changer" for Costco's "competitive moat in grocery."
XLP Consumer Staples Sector SPDR

WFM Bought by AMZN
$42.68

9.62 (29.10%)

06/19/17
KEYB
06/19/17
NO CHANGE
KEYB
Wal-Mart outlook still positive after Whole Foods deal, says KeyBanc
KeyBanc says that Wal-Mart (WMT) stock should be bought in the wake of the Whole Foods (WFM) deal, as the firm remains confident in Wal-Mart's ability to achieve 5%-9% earnings growth in fiscal 2018. The analyst says that the market shares of both Amazon and Wal-Mart have room to grow, and it believes that Amazon will continue to skew towards upper class Americans in the wake of the Whole Foods deal. The firm keeps a $90 price target and an Outperform rating on Wal-Mart.
06/19/17
PIVT
06/19/17
UPGRADE
Target $42
PIVT
Hold
Whole Foods upgraded to Hold from Sell at Pivotal Research
06/19/17
RBCM
06/19/17
NO CHANGE
RBCM
Concerns over dollar stores 'way overdone,' says RBC Capital
RBC Capital analyst Scot Ciccarelli says that concerns about the dollar stores in the wake of the Whole Foods deal were "way overdone,." The analyst thinks that they compete in "a very different segment and customer base" than Whole Foods. Publicly traded dollar stores include Family Dollar (FDO) and Dollar General (DG).
AKS AK Steel

06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
AK Steel upgraded to Buy from Neutral at Longbow
06/19/17
LBOW
06/19/17
NO CHANGE
LBOW
Steel stocks upgraded on positive price outlook at Longbow
As noted earlier, Longbow upgraded steelmakers Nucor (NUE), Steel Dynamics (STLD), U.S. Steel (X) and AK Steel (AKS) to Buy from Hold. After speaking with contacts in the sector, analyst Chris Olin says they expect steel HRC prices to rise $50-$60 per ton, driven by "a (recent) modest uptick in downstream steel orders, inventory adjustments and a large pullback in the number of steel import offers." In the wake of his checks, Olin now sees the chances of near-term government support of the U.S. steel sector in the form of protection from imports at 70%-80%, up from 50% last month. The analyst reports that "some buyers" expect price to rise to $700-$750 per ton following the government action, up from $590-$600 currently. Nucor target $66, Steel Dynamics target $40, U.S. Steel target $30, AK Steel target $10.
05/19/17
LBOW
05/19/17
INITIATION
LBOW
Neutral
AK Steel initiated with a Neutral at Longbow
05/25/17
CLKS
05/25/17
UPGRADE
CLKS
Buy
AK Steel upgraded to Buy from Neutral at Clarksons Platou
SLV iShares Silver Trust

VRX Valeant

06/16/17
CANT
06/16/17
INITIATION
Target $18
CANT
Overweight
Valeant initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Valeant Pharmaceuticals with an Overweight rating and $18 price target. The analyst believes Valeant can reduce its debt to manageable levels over the medium term and thinks new management can post earnings upside in 2019 and beyond. The analyst also thinks the negative media attention placed on the company has reduced significantly from a year ago.
06/14/17
RODM
06/14/17
NO CHANGE
Target $6
RODM
Buy
EyeGate price target lowered to $6 from $10 at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju lowered his price target for EyeGate Pharmaceuticals (EYEG( to $6 after the company granted a subsidiary of Valeant Pharmaceuticals (VRX) exclusive commercial and manufacturing rights to the EyeGate II Delivery System and EGP-437 combination product for treatment of post-operative pain and inflammation in ocular surgery patients. The analyst views the development, along with the top-line data from the first-in-human pilot trial of ocular bandage gel in patients with large corneal epithelial defects, as positive developments and raised his valuation of the company to $112M from $80M. His lowered target reflects higher shares outstanding. Selvaraju reiterates an Outperform rating on EyeGate.
06/09/17
WELS
06/09/17
NO CHANGE
WELS
Outperform
Wells says Valeant's focus on EBITDA ignores rising borrowing costs
After Valeant Pharmaceuticals issued a regulatory filing with financial data for its just sold iNova Pharmaceuticals unit, Wells Fargo analyst David Maris says that while the company is executing deals and reducing absolute debt, "leverage seems to be relatively unchanged." Valeant's focus on EBITDA versus earnings is to have investors "ignore the impact of increased borrowing costs and any impact from potential dilutive equity based financing," Maris tells investors in a research note. Valeant has indicated an equity raise is not off the table, the analyst adds. He has an Underperform rating on the stock with a $9 price target. Valeant in afternoon trading is down 26c to $13.00.
06/08/17
WELS
06/08/17
NO CHANGE
Target $9
WELS
Underperform
Valeant's iNova sale to have minimal impact on debt, says Wells Fargo
Wells Fargo analyst David Maris believes Valeant Pharmaceuticals' sale of iNova Pharmaceuticals for $930M in cash, while possibly "slightly deleveraging," will not have much of an impact on the company's total debt of $28.5B, particularly if the gross proceeds are reduced by tax or other payments. The analyst notes that press reports in September suggested iNova could fetch more than $1B. Maris keeps an Underperform rating on Valeant with a $9 price target. The shares in morning trading are up 8% to $13.18.
X U.S. Steel

06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
U.S. Steel upgraded to Buy from Neutral at Longbow
06/15/17
AXIO
06/15/17
NO CHANGE
AXIO
U.S. Steel is '2019 story,' says Axiom
After meeting with U.S. Steel's new CEO, Dave Burritt, Axiom analyst Gordon Johnson believes that the company is viewing the next 18-24 months as "a restructuring period" that will feature higher spending on "asset revitalization." The analyst quotes Burritt as saying that he expects Congress to pass a "large bi- partisan infrastructure bill in mid-'18, bearing fruit in '19." Johnson now sees U.S. Steel as a "2019 story," and he warns that the company is likely to miss its $1B 2017 EBITDA guidance due to higher spending on asset revitalization. Johnson keeps a Sell rating on the stock.
06/15/17
COWN
06/15/17
NO CHANGE
Target $21
COWN
Market Perform
Cowen maintains cautious stance on U.S. Steel
Cowen analyst Novid Rassouli met with the new CEO of U.S. Steel and noted the company is focused on achieving asset stability over the next one to two years. However, he continues to see the risk of continued operational issues and thus maintains his cautious stance on the shares. Rassouli maintained his Market Perform rating and $21 price target on U.S. Steel.
RAD Rite Aid

06/13/17
BARD
06/13/17
NO CHANGE
Target $96
BARD
Outperform
Walgreens Boots Alliance Q3 results will include deal contingencies, says Baird
Baird analyst Eric Coldwell noted Walgreens Boots Alliance (WBA) will report Q3 results on June 29 and its focus will be on ramping wins in the U.S. and the start of Alliance Rx. He also believes there will be an update on the Rite Aid (RAD) deal and although he would prefer the deal to close, he is prepared for contingency plans, which may include a stock buyback. Coldwell maintained his Outperform rating and $96 price target on Walgreens shares.
05/31/17
JEFF
05/31/17
NO CHANGE
Target $95
JEFF
Buy
Walgreens has upside with or without Rite Aid, says Jefferies
Jefferies analyst Brian Tanquilut believes shares of Walgreens Boots Alliance (WBA) have upside with or without the successful closing of the Rite Aid (RAD) acquisition. If the FTC blocks the deal, Walgreens is likely to put through a "sizeable" repurchase, Tanquilut tells investors in a research note. If the deal is approved, the analyst continues to expect earnings accretion beginning in 2018. The analyst finds it "difficult to handicap the odds" of an FTC approval. Nonetheless, he remains a buyer of Walgreens at current share levels. Tanquilut has a Buy rating on the name with a $95 price target.
04/25/17
GUGG
04/25/17
DOWNGRADE
GUGG
Neutral
Rite Aid downgraded to Neutral from Buy at Guggenheim
05/31/17
COWN
05/31/17
NO CHANGE
Target $5
COWN
Outperform
Cowen believes Walgreens will pursue Rite Aid even if FTC acts to block merger
Cowen analyst Charles Ryhee said the FTC decision on the merger between Walgreens (WBA)and Rite Aid (RAD) is too difficult to call, but he believes although Rite Aid will struggle on its own its value to Walgreens is significant. He also believes the value is well above the deal price range and so expects Walgreens will litigate the decision in an attempt to win an approval. Ryhee reiterated his Outperform rating but lowered his price target to $4.70 from $6.75 on Rite Aid shares.

TODAY'S FREE FLY STORIES

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

16:57
09/22/17
09/22
16:57
09/22/17
16:57
Hot Stocks
Allergan receives refusal to file letter from FDA for Vraylar »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

HON

Honeywell

$141.75

0.89 (0.63%)

, CC

Chemours

$51.79

-0.16 (-0.31%)

16:51
09/22/17
09/22
16:51
09/22/17
16:51
Hot Stocks
Honeywell, Chemours seek rehearing of D.C Court decision regarding SNAP program »

Honeywell (HON) and…

HON

Honeywell

$141.75

0.89 (0.63%)

CC

Chemours

$51.79

-0.16 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$18.60

0.45 (2.48%)

16:46
09/22/17
09/22
16:46
09/22/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Saint Joe Co. »

Fairholme raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.